Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

<b>Background:</b> We developed a hybrid platform using a negative combined with a positive selection strategy to capture circulating tumor cells (CTCs) and detect epidermal growth factor receptor (<i>EGFR</i>) mutations in patients with metastatic lung adenocarcinoma. <b&...

Full description

Bibliographic Details
Main Authors: Shih-Hong Li, Min-Hsien Wu, Hung-Ming Wang, Ping-Chih Hsu, Yueh-Fu Fang, Chih-Liang Wang, Hui-Chun Chu, Hung-Chih Lin, Li-Yu Lee, Ching-Yang Wu, Cheng-Ta Yang, Jen-Shi Chen, Jason Chia-Hsun Hsieh
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:International Journal of Molecular Sciences
Subjects:
liquid biopsy
circulating tumor cells
<i>EGFR</i> mutation
lung adenocarcinoma
Online Access:https://www.mdpi.com/1422-0067/23/18/10661
Description
Summary:<b>Background:</b> We developed a hybrid platform using a negative combined with a positive selection strategy to capture circulating tumor cells (CTCs) and detect epidermal growth factor receptor (<i>EGFR</i>) mutations in patients with metastatic lung adenocarcinoma. <b>Methods:</b> Blood samples were collected from patients with pathology-proven treatment-naïve stage IV lung adenocarcinoma. Genomic DNA was extracted from CTCs collected for <i>EGFR</i> mutational tests. The second set of CTC-EGFR mutational tests were performed after three months of anti-cancer therapy. <b>Results:</b> A total of 80 samples collected from 28 patients enrolled between July 2016 and August 2018. Seventeen patients had <i>EGFR</i> mutations, including Exon 19 deletion (n = 11), <i>L858R</i> (n = 5), and de-novo <i>T790</i> and <i>L858R</i> (n = 1). Concordance between tissue and CTCs before treatment was 88.2% in <i>EGFR</i>- mutant patients and 90.9% in non-mutant patients. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of <i>EGFR</i> mutation tests for CTCs were 89.3%, 88.2%, 90.9%, 93.8%, and 83.3%, respectively. <b>Conclusions</b>: CTCs captured by a hybrid platform using a negative and positive selection strategy may serve as a suitable and reliable source of lung cancer tumor DNA for detecting <i>EGFR</i> mutations, including T790M.
ISSN:1661-6596
1422-0067

Similar Items